Determination of Meropenem, Ceftazidime and Piperacillin Levels in Serum and Meropenem in Cerebrospinal Fluid by Liquid Chromatography for Routine Quantification
Stefan Günther1,2,3, Andreas Reimer1, Horst Vogl1, Stephan Spenke2, Hanns-Christian Dinges3, Ann-Kristin Schubert4, Leopold HJ Eberhart4, Götz Geldner2

Abstract
Objective: Therapeutic drug monitoring (TDM) of β-lactam antibiotics is commonly used to prevent treatment failures in critically ill patients. A quick and simple high-performance liquid chromatography (HPLC) assay for the determination of meropenem, ceftazidime and piperacillin in human serum and meopenem in cerebrospinal fluid (CSF) was developed in this study.

Methods: The method used an Atlantis® T3 5.0µm stationary phase. The mobile phase A contained water (99.4% m/m) and formic acid (0.6% m/m) (pH 2.30). The mobile phase B contained acetonitrile (93.6% m/m), water (6% m/m) and formic acid (0.4% m/m). The method used gradient elution to determine meropenem, ceftazidime and piperacillin. UV absorbance detection at 309nm, 258nm, 235nm and 260nm respectively was used. For sample preparation, an internal standard was added, and acetonitrile/methanol was added for protein precipitation.

Results: The method was investigated for linearity, specificity, accuracy, and precision. Stability of the antibiotic substances and internal standard was assessed. The retention time of meropenem was 7.222min, the single run time was 23min. Meropenem was quantified from the lower limit of quantification (0.1mg/l in serum and CSF) to the upper limit of quantification (100mg/l in serum and 25mg/l in CSF). In routine analysis of meropenem samples, a high interindividual variability of serum and CSF levels was observed and the mean CSF/serum ratio was 0.129 ± 0.092. An external validation was passed for meropenem, ceftazidime and piperacillin using the presented protocol.

Conclusion: The developed assay enable studying correlations between the applied dosage, serum concentration and CSF concentration of meropenem. Additionally, ceftazidime and piperacillin can be determined in human serum. Further studies with a higher number of samples can be performed to investigate the penetration of meropenem into CSF. The presented protocol can be recommended to measure the substances in serum and CSF.

Keywords: Meropenem, Ceftazidime, Piperacillin, Therapeutic drug monitoring, HPLC, validation, human serum, cerebrospinal fluid

Background
Meropenem (4R,5S,6S)-3-[[3S,5S]-5-[[Dimethylamino]carbonyl]-3-
pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-l-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid; figure 1[1]) is a carbapenem derivative with a broad spectrum of activity against gram-positive and gram-negative bacteria. It belongs to the β-lactam antibiotics and therefore penetrates the bacterial cell wall and inhibits the cell wall synthesis[2]. Due to its good stability against β-lactamases, there are only few resistances and it is used as an antibiotic of last resort on intensive care units (ICUs) [3, 4]. Meropenem is frequently recommended for the treatment of nosocomial infections like ventriculitis, which is a common complication when external ventricular drains (EVD) are used in therapy of acute subarachnoid hemorrhage, intraventricular bleedings or other acute intracranial pathologies [5]. Taking into account the emerging rise of antimicrobial resistance and the few new antimicrobials available for clinical uses, the dose optimization strategy for existing drug therapies becomes increasingly important to achieve the maximum therapeutic efficacy [3, 6, 7]. Therapeutic drug monitoring (TDM) of β-lactam antibiotics is a frequently used tool to optimize the treatment with several antibiotics. Especially on ICUs TDM allows accurate dosing in critically ill patients that have altered pharmacokinetics due to various stages of organ failure and are therefore prone to over- and under dosing [8-10]. However, the main challenge for critical care physicians remains achieving, maintaining and controlling appropriate antibiotic concentrations in target tissues. In cases of ventriculitis, the blood-CSF-barrier limits the penetration of meropenem to its target tissue [11]. Recent analysis indicate highly variable penetration of meropenem into CSF in ventriculitis patients [12, 13]. Furthermore, some data show that traditional dosing of meropenem (3 x 2g as intermittent infusion) cannot achieve CSF concentrations above the minimum inhibitory concentration (MIC) [13]. To prevent therapy failure continuous infusion of β-lactam antibiotics is suggested for maintaining concentrations over the dosing interval [14]. Moreover, standard doses of meropenem (maximum 6g/24h [15]) could be insufficient, leading to dosage regimes higher than standard [16]. Using median initial doses of 8.8g/24h and TDM-guided dose optimization ensured sufficient CSF concentrations in all patients within 48h [16]. To satisfy the need of intensive care units, we describe a simple method to determine meropenem in human serum and cerebrospinal fluid. The aim of this study is to demonstrate the development, validation and routine use of internal standard high-performance liquid chromatography assay for meropenem in human serum and cerebrospinal fluid. Additionally this method is able to determine ceftazidime and piperacillin in human serum.

Materials and Methods

Antibacterial agents and other substances

We used meropenem powder for solution for injection/infusion, commercially available from Dr. Friedrich Eberth Arzneimittel (Ursensollen, Germany), piperacillin/tazobactam powder for solution for injection/infusion, commercially available from Fresenius Kabi Deutschland (Bad Homburg, Germany) and ceftazidime powder for solution for injection/infusion, commercially available from Dr. Friedrich Eberth Arzneimittel (Ursensollen, Germany). Also cefotaxime powder for solution for injection/infusion, commercially available from Fresenius Kabi Deutschland (Bad Homburg, Germany), cefazolin powder for solution for injection/infusion, commercially available from MIP Pharma GmbH (Blieskastel, Germany) and porcine serum from bio&sell GmbH (Feuchtwangen, Germany). Patient serum and patient cerebrospinal fluid were received from ICUs for TDM.

Solvents

We purchased formic acid, sodium hydroxide, methanol (HPLC grade) and acetonitrile (HPLC grade) from Th. Geyer GmbH & Co. KG (Renningen, Germany). Purified water was purchased from Fresenius Kabi Deutschland GmbH (Bad Homburg, Germany).

High-performance liquid chromatography (HPLC)

We used a high-performance liquid chromatography system by Shimadzu that contains a temperate autosampler, column oven and UV-Vis detector. Labsolution (Shimadzu, Germany) software was used to control the chromatographic system of the double internal standard based method. The stationary phase was Atlantis® T3 5μm, 15cm x 4.6mm Column (Waters Corporation, Milford, MA, USA).

The mobile phase A contained water (99.4% m/m), formic acid (0.6% m/m) and was adjusted to pH 2.30 by the addition of 1M sodium hydroxide. The mobile phase B contained acetonitrile (93.6% m/m), water (6% m/m) and formic acid (0.4% m/m). We used a gradient elution method consisting of mobile Phase A and mobile phase B as seen in table 1.

The pump flow rate was 1.0ml/min. UV absorbance detection was used at 309nm (meropenem), 235nm (piperacillin), 258nm (ceftazidime), 260nm (cefotaxime) and 270nm (cefazolin). The column oven temperature was
set to 20°C in routine. The method was running for 23min, the median retention times were 7.222min for meropenem, 17.541min for piperacillin, 6.704min for ceftazidime, 9.861min for cefotaxime and 12.105min for cefazolin at 20°C.

**Reference standards**

To determine the content of the commercially available powders for solution for injection/infusion we used chemical reference substances (CRS). Meropenem trihydrate CRS (content 86.9%), piperacillin CRS (content 95.2%), ceftazidime CRS (content 85.5%), cefotaxime acid CRS (content 90.6%) and cefazolin (content 99.2%) were purchased from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany).

**Sample preparation**

We prepared samples by mixing 250µl patient serum or CSF with 50µl internal standard (cefotaxime 125mg/l and cefazolin 125mg/l) and 500µl acetonitrile/methanol (1:1) for precipitation. The samples were mixed for 10s and centrifuged at 10 000 RPM for 10min. 200µl of the supernatant were diluted with 460µl water and 50µl of this mixture was injected.

**Results**

**Selectivity**

Selectivity of the analytical method was proven using six individual sources of the appropriate blank matrix (human serum), which were individually analyzed and evaluated for interference. No relevant interference was detected but to prevent interference with the internal standard we decided to use a mixture of two internal standards. If there is an interference with cefotaxime we can use cefazolin to analyze the patient sample. Interference may occur in patients who received cefotaxime or cefazolin in earlier therapy regimes.

**Carry-over**

To prevent carry-over we injected blank samples after high concentration samples [17]. There was no carry-over detected in the blank samples.

![Table 1: Gradient time program for HPLC](image)

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Solvent B concentration (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01</td>
<td>10</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>11</td>
<td>35</td>
</tr>
<tr>
<td>15</td>
<td>35</td>
</tr>
<tr>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>23</td>
<td>10</td>
</tr>
</tbody>
</table>

**Lower limit of quantification**

The lower limit of quantification is defined as the lowest concentration of analyte in a sample, which can reliably be quantified, with an acceptable accuracy and precision. LLOQ is aimed to be at least 5 times the signal of a blank sample [17]. For this analytical method, the LLOQ for meropenem is 0.1mg/l in serum and CSF, 0.2mg/l for ceftazidime in serum and 10mg/l for piperacillin in serum.

**Calibration curve**

For time-dependent drugs, the main parameter associated with therapeutic success is the percentage of time that the levels of antibiotics at the infection site exceed the minimum inhibitory concentration (%f T > MIC) of the pathogen [18]. Due to the clinically sensible breakpoint against the pathogenic *Pseudomonas spp*. at 2 mg/l [19] we defined the target concentration in CSF > 2mg/l. For meropenem levels in serum we defined target concentrations of 8 – 16mg/l (100% fT > 4x MIC - 100% fT > 6x MIC). Ceftazidime serum target concentrations 32 – 48mg/l (100% fT > 4x MIC - 100% fT > 6x MIC) and piperacillin serum target concentrations 64 – 96mg/l (100% fT > 4x MIC - 100% fT > 6x MIC) due to their MIC breakpoints against *Pseudomonas spp*. [19].

According to the target concentration range a minimum of six calibration concentration levels were used for each method [17]. The LLOQ is defined being the lowest calibration standard and the highest calibration standard defines the upper limit of quantification (ULOQ) as seen in table 2 [17]. LLOQ is 0.1mg/l for meropenem in serum and liquor, the ULOQ is 100mg/l in serum and 25mg/l in CSF. LLOQ is 0.2mg/l for ceftazidime in serum; the ULOQ is 75mg/l in serum. LLOQ is 10mg/l for piperacillin in serum; the ULOQ is 200mg/l in serum.

For the calibration standards, we used porcine serum and residual material of human CSF. To prepare the calibration standards we spiked 200µl matrix with 50µl antibiotic solution (target concentration level x5 mg/l). The following steps were performed analog the sample preparation. All calibration curves analysis used freshly spiked samples. The correlation between mean area ratio and concentration ratio was strong for all calibration curves (R² >0.9999).

**Accuracy**

The accuracy describes the closeness of the determined value obtained by the method to the nominal concentration of the analyte. Accuracy was assessed on samples spiked with known amounts of the analyte. These samples were spiked independently from the calibration standards and were analyzed against the calibration curve. For the validation of the accuracy, we analyzed LLOQ, low, medium and high concentration samples. The mean concentration within a value of 15% from the nominal values is commonly considered acceptable, except for the LLOQ, which is acceptable.

within 20% of the nominal value [17]. The accuracy was demonstrated with all mean concentrations between 88.56% and 100.82% of the nominal value.

**Precision**

The precision of the analytical method describes the closeness of repeated individual measures of analyte in the same sample. Precision can be expressed as the relative standard deviation (RSD). Precision of the analytical method should be demonstrated for the LLOQ, low, medium and high sample concentrations. The RSD value should not exceed 15% for the low, medium and high concentration samples, except for the LLOQ, which should not exceed 20% [17]. Precision was demonstrated for every antibiotic substance with all RSD values ranging between 0.64% and 12.95%.

**Stability**

The low stability of meropenem in aqueous solutions or biological fluids is often reported in literature [20-22]. Even transport between clinic and laboratory is difficult due to the limited stability [21]. To detect stability, we analyzed the degradation of meropenem, ceftazidime and piperacillin under relevant conditions. Therefore, we evaluated the stability of meropenem in spiked porcine serum and CSF after sample preparation at 5°C. This simulates the conditions in our autosampler and no relevant degradation was detected over 15h as seen in figure 2. Additionally we analyzed the stability of meropenem, ceftazidime and piperacillin in biological matrix.

We spiked human serum with a mixture of all three antibiotics and measured the concentrations at the beginning, after 24h and 48h. One sample was stored at 5°C, one in the freezer at -32°C and one at ambient temperature 25°C. The concentrations at 25°C decreased very fast compared to the samples at 5°C and -32°C as shown for meropenem.

### Table 2: Antibiotic concentration levels used for the calibration curves. Every calibration sample contains 25mg/l internal standard (cefotaxime and cefazolin).

<table>
<thead>
<tr>
<th>Conc. Level</th>
<th>Meropenem serum</th>
<th>Meropenem CSF</th>
<th>Ceftazidime serum</th>
<th>Piperacillin serum</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>0.1 mg/l</td>
<td>0.1 mg/l</td>
<td>0.2 mg/l</td>
<td>10 mg/l</td>
</tr>
<tr>
<td>#2</td>
<td>0.2 mg/l</td>
<td>0.2 mg/l</td>
<td>0.5 mg/l</td>
<td>25 mg/l</td>
</tr>
<tr>
<td>#3</td>
<td>0.5 mg/l</td>
<td>0.5 mg/l</td>
<td>1 mg/l</td>
<td>50 mg/l</td>
</tr>
<tr>
<td>#4</td>
<td>1 mg/l</td>
<td>1 mg/l</td>
<td>2.5 mg/l</td>
<td>100 mg/l</td>
</tr>
<tr>
<td>#5</td>
<td>5 mg/l</td>
<td>2.5 mg/l</td>
<td>5 mg/l</td>
<td>160 mg/l</td>
</tr>
<tr>
<td>#6</td>
<td>12.5 mg/l</td>
<td>5 mg/l</td>
<td>10 mg/l</td>
<td>200 mg/l</td>
</tr>
<tr>
<td>#7</td>
<td>25 mg/l</td>
<td>10 mg/l</td>
<td>20 mg/l</td>
<td>not used</td>
</tr>
<tr>
<td>#8</td>
<td>50 mg/l</td>
<td>25 mg/l</td>
<td>30 mg/l</td>
<td>not used</td>
</tr>
<tr>
<td>#9</td>
<td>100 mg/l</td>
<td>not used</td>
<td>50 mg/l</td>
<td>not used</td>
</tr>
<tr>
<td>#10</td>
<td>not used</td>
<td>not used</td>
<td>75 mg/l</td>
<td>not used</td>
</tr>
</tbody>
</table>

![Stability after sample preparation at 5°C](image)

**Figure 2:** Stability of meropenem in porcine serum and CSF after sample preparation at 5°C.
The same degradation progress was detected for ceftazidime and piperacillin. At 25°C the value 90% of start concentration was passed within the first 24h and at 5°C after 48h. At -32°C the value 90% of start concentration was not passed within 48h. Consequently, we concluded to freeze the collected patient samples and analyze them within 24h after collection.

Quality control samples

We performed quality control samples to show our system and methods work as we expect on days with analysis of unknown samples. Therefore, high and low concentration samples were prepared out of antibiotic (meropenem + ceftazidime + piperacillin) and internal standard (ceftaxime + cefazolin) stock solution with porcine serum. The low concentration sample was spiked with 4mg/l meropenem, 16mg/l ceftazidime and 34mg/l piperacillin. The high concentration sample was spiked with 16mg/l meropenem, 65mg/l ceftazidime and 137mg/l piperacillin. We defined the acceptable concentration range of the measured antibiotics with ±7% and the acceptable area range of internal standard with ±7.5% due to the recommendation of the EMA guideline on bioanalytical method validation17. They recommend ranges of ±15% but we decided to define closer limits with ±7% and ±7.5%.

External validation

To verify the performance of the method an external validation assay was passed. This assay was offered by INSTAND (Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e.V., Düsseldorf). The achieved certificate is valid for 12 months and proves that two samples with unknown concentration of meropenem, ceftazidime and piperacillin were analyzed correctly within acceptable limits. The results are shown in table 3.

Routine analysis

The method we described here is routinely used in our laboratory to determine meropenem levels in human sera and CSF. Within the setting described above, we measured 64 pairs of simultaneous collected human serum and CSF samples from critically ill patients on intensive care units. The serum levels of meropenem ranged between 5.4mg/l up to 49.3mg/l (mean 18.6mg/l ± 7.6mg/l, median 16.4mg/l). The CSF levels of meropenem ranged between 0.3mg/l up to 17.9mg/l (mean 2.6mg/l ± 2.6mg/l, median 1.9mg/l). For our measurements, the mean CSF/serum ratio was 0.129 ± 0.092. Patient characteristics and dosage regimes are collected in table 4.

![Figure 3: Degradation of meropenem in human serum at 5°C, 25°C and -32°C over 48h](image)

Table 3: Results of the external validation by INSTAND

<table>
<thead>
<tr>
<th>Substance</th>
<th>Sample</th>
<th>Unit</th>
<th>Measured conc.</th>
<th>Target conc.</th>
<th>Lower limit</th>
<th>Upper limit</th>
<th>Deviation</th>
<th>Result +/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftazidime</td>
<td>1</td>
<td>mg/l</td>
<td>3.80</td>
<td>4.08</td>
<td>2.86</td>
<td>5.30</td>
<td>-6.9%</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>mg/l</td>
<td>58.9</td>
<td>63.2</td>
<td>44.2</td>
<td>82.2</td>
<td>-6.8%</td>
<td>+</td>
</tr>
<tr>
<td>Meropenem</td>
<td>1</td>
<td>mg/l</td>
<td>14.6</td>
<td>17.4</td>
<td>12.2</td>
<td>22.6</td>
<td>-16.1%</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>mg/l</td>
<td>120</td>
<td>132</td>
<td>92.4</td>
<td>172</td>
<td>-9.1%</td>
<td>+</td>
</tr>
<tr>
<td>Piperacillin</td>
<td>1</td>
<td>mg/l</td>
<td>46.1</td>
<td>48.3</td>
<td>33.8</td>
<td>62.8</td>
<td>-4.6%</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>mg/l</td>
<td>14.6</td>
<td>17.4</td>
<td>12.2</td>
<td>22.6</td>
<td>-16.1%</td>
<td>+</td>
</tr>
</tbody>
</table>

large standard deviations. If these analysis are compared with
of serum levels, CSF levels and the CSF/serum ratio due to
Blassmann et al. and suggest a high interindividual variability
with a mean CSF/serum ratio of 12.9% support the data from
a very poor CNS penetration. Our data from routine analysis
of serum and CSF levels the mean ratio was 0.129 ± 0.092.
Continuous infusion of meropenem; this gave us also the
We measured serum and CSF levels at the same time during
et al. who is reporting a median CSF/plasma penetration of
under dosing [25]. These results are in line with Blassmann
a surrogate parameter of CSF concentrations may lead to
whether meropenem plasma concentrations simply used as
nature [23, 24]. Additionally results were published on
β-lactams, especially carbapenems, due to their hydrophilic
A reduced distribution into CSF has been documented for
reported CSF penetration of between 21 and 39% in patients
with bacterial meningitis [27, 28], it is suspected that dosing
regimens for meropenem in patients with meningitis cannot be
extrapolated to patients with ventriculitis.

Our data contains two patients with proven or suspected
mениgitis in which the measured CSF/serum ratio are higher
than the mean CSF/serum ratio (13.7% and 23.3% compared
with mean 12.9%). It is likely, that drug penetration in
inflamed meninges is greater than in patients with non-
inflamed. Consequently, in critically ill patients with CNS
infections, the standard dosing regimen of meropenem with
6g daily does not predictively achieve optimal plasma and
CSF concentrations in all patients. Results like these push
the need for TDM of meropenem in plasma and in CSF to
avoid either the risk of dose-dependent toxicity or that of
treatment failure. The development of meropenem-induced
 toxicity is significantly affected in patients with a high serum
meropenem concentration. The threshold concentrations
for which there is 50% risk of developing a neurotoxicity
event is described with meropenem c min = 64.2mg/l and a
nephrotoxicity event with c min = 44.45mg/l [29].

Furthermore, optimized dosing strategies like
administration of higher than standard dosages or
administration by continuous infusion should be taken into
consideration. Continuous infusion has been demonstrated to
improve PK/PD target attainment in various further studies
of time-dependent antibiotics [30-32]. Recommended daily
doses for meropenem are 6g in adults [5]. High initial
meropenem doses (median 8.8g/24h by continuous infusion)
together with dose adjustments according to TDM ensured
sufficient CSF concentrations in all patients according to
Tiede et al [16] Consistent evidence is now available showing
that therapeutic drug monitoring and guided individual dose
optimization of meropenem is justified and feasible in clinical
practice to reduce underexposure, improve tolerability and
possibly response to therapy [16].

We have demonstrated meropenem, ceftazidime and
piperacillin to be stable in human serum up to 48h in frozen
condition at -32°C. This is important because it was shown
that meropenem was unstable when stored at temperatures
above 4°C [20-22]. Furthermore, meropenem, ceftazidime
and piperacillin were stable after treatment with acetonitrile/
methanol. Accordingly, the prepared samples can be assayed
under storage conditions of 5°C within 24h period and no
relevant loss of meropenem, ceftazidime or piperacillin was
detected.

Conclusion

In the present study, we developed a simple method for the
quantification of meropenem in human serum and CSF. The
developed method could be easily and quickly performed and
enabled the quantification of meropenem in patient samples

---

### Table 4: Patient characteristics and dosage regimes

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>30</td>
</tr>
<tr>
<td>Gender (No. M/no. F)</td>
<td>19/11</td>
</tr>
<tr>
<td>Mean age (yr)</td>
<td>53.0</td>
</tr>
<tr>
<td>Mean body weight (kg)</td>
<td>80.3</td>
</tr>
<tr>
<td>Mean serum conc. (mg/l)</td>
<td>18.7 ± 7.6</td>
</tr>
<tr>
<td>Mean CSF conc. (mg/l)</td>
<td>2.6 ± 2.6</td>
</tr>
<tr>
<td>Mean CSF-serum ratio</td>
<td>0.129 ± 0.092</td>
</tr>
<tr>
<td>Dose continuous 8000mg/24h</td>
<td>14</td>
</tr>
<tr>
<td>Dose continuous 6000mg/24h</td>
<td>46</td>
</tr>
<tr>
<td>Dose continuous 4000mg/24h</td>
<td>2</td>
</tr>
<tr>
<td>Dose continuous 3000mg/24h</td>
<td>1</td>
</tr>
<tr>
<td>Dose continuous 2000mg/24h</td>
<td>1</td>
</tr>
<tr>
<td>Mean dose continuous /24h (mg)</td>
<td>6.3 ± 1.1</td>
</tr>
<tr>
<td>Indication ventriculitis</td>
<td>14</td>
</tr>
<tr>
<td>Indication meningitis</td>
<td>2</td>
</tr>
<tr>
<td>Indication subarachnoid hemorrhage</td>
<td>1</td>
</tr>
<tr>
<td>Indication brainstem abscess</td>
<td>2</td>
</tr>
<tr>
<td>Indication shunt infection</td>
<td>3</td>
</tr>
<tr>
<td>Indication unknown</td>
<td>8</td>
</tr>
</tbody>
</table>

Discussion

The developed assay is reproducible, accurate, precise,
and linear across the range of the calibration curves. The
preparation of our samples is quick and simple. The HPLC
assay time of 23min is acceptable for the processing of
samples for routine TDM.

Previous studies described large interindividual variability
in the concentrations of meropenem in plasma and CSF11.
A reduced distribution into CSF has been documented for
β-lactams, especially carbapenems, due to their hydrophilic
nature [23, 24]. Additionally results were published on
whether meropenem plasma concentrations simply used as
a surrogate parameter of CSF concentrations may lead to
under dosing [25]. These results are in line with Blassmann
et al. who is reporting a median CSF/plasma penetration of
9% in 21 neurocritical care patients with ventriculitis [13].
We measured serum and CSF levels at the same time during
continuous infusion of meropenem; this gave us also the
chance to calculate the CSF/serum ratio and for our 64 pairs
of serum and CSF levels the mean ratio was 0.129 ± 0.092.
Compared to the non β-lactam antibiotic linezolid with a
reported CSF/serum ratio of 0.71 ± 0.16 [26], meropenem has
a very poor CNS penetration. Our data from routine analysis
with a mean CSF/serum ratio of 12.9% support the data from
Blassmann et al. and suggest a high interindividual variability
of serum levels, CSF levels and the CSF/serum ratio due to
large standard deviations. If these analysis are compared with
for routine TDM. In the future, this method can be used to evaluate the serum and CSF concentrations of meropenem in critically ill patients. Consequently, meropenem dosage regimes should be tailored to individual patients. This is essential because our data suggests that there is a high variability in serum concentrations, CSF concentrations and CSF/serum ratios.

Furthermore, the developed method creates the chance to study CSF penetration of meropenem because the simplest way to study the entry of drugs into the CNS is to measure drug concentrations in the CSF during a continuous drug infusion\(^1\). Additionally, this method enables to quantify ceftazidime and piperacillin concentrations in human serum. Our investigation was limited due to the lack of information about clinical outcomes of the patients and the lack of microbiological analysis. In conclusion, our results are in line with other studies that showed a high variability of serum and CSF levels of meropenem, and future studies can be performed using the method described above.

**Ethics approval**

Ethics Committee of “Ärztekammer Baden-Württemberg” in Stuttgart, Germany (authorization number: F-2020-057).

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

None declared.

**Contributors**


**Acknowledgments**

None.

**References**